We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Case report reveals successful dasatinib treatment in systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion refractory to MEK inhibition, highlighting actionable kinase targets.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: